MAMMÔ 2026 Day 2 Highlights: From Adjuvant Optimization to Metastatic Breast Cancer, ADCs and Precision Treatment
OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition
French Court Recognizes Flight Attendant’s Breast Cancer as Occupational Disease
Ani Hmayakyan: How is Lightning McQueen Connected to 25 Years of Progress in Melanoma Treatment?
Maira Caleffi: MAMMÔ 2026 Emphasizes That Women With Suspected Cancer Cannot Wait
KEYNOTE-B49 at ESMO 2026: Can Immunotherapy Find a Role in HR+/HER2− Breast Cancer?
Mohammad Hojouj: Honored to Join OncoDaily as an ESMO 2026 Ambassador
Arthur Furlan: ODC Life Sciences and OncoDaily Partner to Expand Clinical Trials in LATAM
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
